文献速递复苏、休克与脓毒症心脑血管急症

血管加压素联合甲泼尼龙对院内心搏骤停患者自主循环恢复的影响:一项随机临床试验

Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论院内心搏骤停中,肾上腺素后加用血管加压素20 IU联合甲泼尼龙40 mg可提高自主循环恢复率,但30天生存和神经功能结局未改善。

该多中心、随机、双盲、安慰剂对照试验在丹麦10家医院纳入512例院内心搏骤停成人患者,随机接受血管加压素联合甲泼尼龙(n=245)或安慰剂(n=267)。首剂在首次肾上腺素后给予血管加压素20 IU和甲泼尼龙40 mg,之后每次追加肾上腺素时追加研究药物,最多4剂。

要点

  • 院内心搏骤停成人患者,在首次肾上腺素后给予血管加压素20 IU联合甲泼尼龙40 mg,自主循环恢复率从33%提高到42%(RR 1.30,95%CI 1.03-1.63)。
  • 每次追加肾上腺素时追加研究药物,最多4剂;该方案为研究方案,非通用推荐剂量。
  • 自主循环恢复患者中,干预组高血糖77% vs 安慰剂组73%,高钠血症28% vs 31%。

适用人群与场景

  • 丹麦10家医院收治的院内心搏骤停成人患者,年龄均值71岁(SD 13),男性64%(322/501)。
  • 纳入标准为院内心搏骤停且符合随机化条件;排除标准原文未详细列出,仅说明501例符合全部纳入且无排除标准。
  • 场景为院内(非院前)心搏骤停复苏过程中。

诊断标准与关键阈值

  • 主要终点为自主循环恢复(ROSC)。
  • 次要终点包括30天生存和30天良好神经功能结局,良好神经功能结局定义为脑功能分级(CPC)评分1或2。
  • 原文未提及ROSC的具体判定标准或复苏终止阈值。

处置流程与药物剂量

  • 第一步:按常规院内心搏骤停复苏流程给予首次肾上腺素。
  • 第二步:首次肾上腺素后给予首剂血管加压素20 IU联合甲泼尼龙40 mg(或对应安慰剂),静脉给药途径原文未明确写出。
  • 第三步:每次追加肾上腺素后追加血管加压素或对应安慰剂,最多4剂;甲泼尼龙是否随追加剂量重复原文未明确。
  • 原文未提及目标血压、复苏后循环支持目标或其他药物剂量。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 多中心、随机、双盲、安慰剂对照试验,丹麦10家医院,2018年10月15日至2021年1月21日纳入512例,501例纳入分析(干预组237例,安慰剂组264例)。
  • ROSC患者不良事件:高血糖干预组77%(77例)vs 安慰剂组73%(63例);高钠血症干预组28%(28例)vs 安慰剂组31%(27例)。

证据类型、等级与局限

  • 证据类型:多中心随机双盲安慰剂对照试验(RCT)。
  • 局限:原文结论指出长期生存获益或 harm 存在不确定性;试验在丹麦10家医院进行,人群和复苏体系外推需谨慎;样本量501例,30天生存和神经功能结局事件数少。

对床旁实践的改变

  • 对于院内心搏骤停成人患者,可考虑在首次肾上腺素后加用血管加压素20 IU联合甲泼尼龙40 mg以提高ROSC概率,但需告知长期生存和神经功能结局未改善。
  • 该联合方案不应被理解为可改善30天生存或神经功能结局的常规推荐;原文明确长期获益或 harm 存在不确定性。
  • 用药方案为研究方案(首剂后每次追加肾上腺素追加研究药物,最多4剂),临床使用时需注意高血糖和高钠血症的发生。

指南或共识出处

  • 原文未提及指南或共识出处;试验注册号ClinicalTrials.gov NCT03640949。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Previous trials have suggested that vasopressin and methylprednisolone administered during in-hospital cardiac arrest might improve outcomes.

OBJECTIVE: To determine whether the combination of vasopressin and methylprednisolone administered during in-hospital cardiac arrest improves return of spontaneous circulation.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind, placebo-controlled trial conducted at 10 hospitals in Denmark. A total of 512 adult patients with in-hospital cardiac arrest were included between October 15, 2018, and January 21, 2021. The last 90-day follow-up was on April 21, 2021.

INTERVENTION: Patients were randomized to receive a combination of vasopressin and methylprednisolone (n = 245) or placebo (n = 267). The first dose of vasopressin (20 IU) and methylprednisolone (40 mg), or corresponding placebo, was administered after the first dose of epinephrine. Additional doses of vasopressin or corresponding placebo were administered after each additional dose of epinephrine for a maximum of 4 doses.

MAIN OUTCOMES AND MEASURES: The primary outcome was return of spontaneous circulation. Secondary outcomes included survival and favorable neurologic outcome at 30 days (Cerebral Performance Category score of 1 or 2).

RESULTS: Among 512 patients who were randomized, 501 met all inclusion and no exclusion criteria and were included in the analysis (mean [SD] age, 71 [13] years; 322 men [64%]). One hundred of 237 patients (42%) in the vasopressin and methylprednisolone group and 86 of 264 patients (33%) in the placebo group achieved return of spontaneous circulation (risk ratio, 1.30 [95% CI, 1.03-1.63]; risk difference, 9.6% [95% CI, 1.1%-18.0%]; P = .03). At 30 days, 23 patients (9.7%) in the intervention group and 31 patients (12%) in the placebo group were alive (risk ratio, 0.83 [95% CI, 0.50-1.37]; risk difference: -2.0% [95% CI, -7.5% to 3.5%]; P = .48). A favorable neurologic outcome was observed in 18 patients (7.6%) in the intervention group and 20 patients (7.6%) in the placebo group at 30 days (risk ratio, 1.00 [95% CI, 0.55-1.83]; risk difference, 0.0% [95% CI, -4.7% to 4.9%]; P > .99). In patients with return of spontaneous circulation, hyperglycemia occurred in 77 (77%) in the intervention group and 63 (73%) in the placebo group. Hypernatremia occurred in 28 (28%) and 27 (31%), in the intervention and placebo groups, respectively.

CONCLUSIONS AND RELEVANCE: Among patients with in-hospital cardiac arrest, administration of vasopressin and methylprednisolone, compared with placebo, significantly increased the likelihood of return of spontaneous circulation. However, there is uncertainty whether this treatment results in benefit or harm for long-term survival.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03640949.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Andersen LW, Isbye D, Kjærgaard J, et al. Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2021. PMID: 34587236. doi:10.1001/jama.2021.16628

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。